Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial

EFV-TDF-FTC showed significantly greater increases in CD4/CD8 ratio ≥1.0 or MTMR beyond treatment week 96. Additional studies are necessary to better understand the impact of these findings.